HASBROUCK HEIGHTS, N.J., November 13 /CNW/ - Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) announced today its financial results for the
quarter ended September 30, 2007. Nymox reported a net loss of $1,386,084, or
$0.05 per share for the third quarter of 2007, compared to $1,238,833, or
$0.04 per share for same period in 2006. Product sales amounted to $277,921
for the nine months ending September 30, 2007, compared to $353,962 for the
same period in 2006. The weighted average number of common shares at the
quarter ended September 30, 2007 was 29,182,571, compared to 27,789,196 at
September 30, 2006.
Nymox Pharmaceutical Corporation is a biotechnology company engaged in
the research and development of therapeutics and diagnostics, with a
particular emphasis on products targeted for the unmet needs of the aging
population. Currently Nymox has three products on the market, and a healthy
pipeline of drug and diagnostic products. The Company also has several hundred
patents and patent applications. The Company is in late stage development of
NX-1207, a drug for benign prostatic hyperplasia (BPH). Nymox has a number of
drugs in development for E. coli infection, Alzheimer's disease, oncology, and
infectious disease. The Company markets NicAlert(TM) and TobacAlert(TM) tests
for measuring tobacco product exposure, and AlzheimAlert(TM), a test to aid in
the diagnosis of Alzheimer's disease.
More information about Nymox is available at www.nymox.com, email:
email@example.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of 1995
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and the actual results and
future events could differ materially from management's current expectations.
Such factors are detailed from time to time in Nymox's filings with the United
States Securities and Exchange Commission and other regulatory authorities.
For further information:
For further information: Nymox Pharmaceutical Corporation Roy Wolvin,